Abstract:Objective:To evaluate the short-term efficacy and safety of a single cycle of high-dose dexamethasone(HD-DXM) combined with recombinant human interleukin-11(rhIL-11) in adult patients with severe primary immune thrombocytopenia(ITP).Methods:Two groups of patients with severe ITP received HD-DXM therapy in combination with rhIL-11(n=26) or not in combination with rhIL-11(n=19).The overall response rates(OR),complete response rates(CR),time to initial response,peak platelet counts and side effects between the two groups were compared.Clinical characteristics possibly correlated with the efficacy of rhIL-11 was also analyzed.Results: The OR and CR in patients treated with HD-DXM combined with rhIL-11 were 80.8% and 57.7%,and those were 47.4% and 26.3% in patients treated with HD-DXM(P all <0.05).The peak platelet counts were(129.6±58.4)×109/L in patients received HD-DXM combined with rhIL-11 and(97.2±45.2) ×109/L in patients received HD-DXM(P=0.05),and there was no statistical significant difference in the onset time between the two groups(P>0.05).There was significant difference in the duration of safety range between the two groups(P<0.01).No significant correlation was found between the peak platelet counts after rhIL-11 treatment and megakaryocyte counts,age,or gender in patients received HD-DXM combined with rhIL-11.(P>0.05).Patients tolerated rhIL-11 well.Conclusions: RhIL-11 can improve the efficacy of HD-DXM in treating severe ITP.

Efficacy of High-dose Dexamethasone in Combination with Recombinant Human Interleukin-11 in Adult Patients with Severe Primary Immune Thrombocytopenia